Delayed hypersensitivity to low-molecular-weight heparin (LMWH) in pregnancy.
Schapkaitz
E
E
Department of Haematology and Molecular Medicine, National Health Laboratory Service, Johannesburg. bradgelbart@icon.co.za
Jacobson
B F
BF
D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage; D003348:Cortisone / Q000008:administration & dosage; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use; D009824:Ointments; D011134:Polysaccharides / Q000008:administration & dosage; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control*; D011256:Pregnancy Outcome; D011655:Pulmonary Embolism / Q000517:prevention & control*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D009824:Ointments; D011134:Polysaccharides; D000077425:Fondaparinux; D003348:Cortisone